Popular terms

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Factor patents



      

This page is updated frequently with new Factor-related patent applications.




Date/App# patent app List of recent Factor-related patents
04/07/16
20160097779 
 Methods and compositions for diagnosis and prognosis of renal injury and renal failure patent thumbnailMethods and compositions for diagnosis and prognosis of renal injury and renal failure
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of heat shock protein beta-1, wap four-disulfide core domain protein 2, choriogonadotropin subunit beta, placenta growth factor, and mitochondrial 60 kda heat shock protein as diagnostic and prognostic biomarkers in renal injuries..
Astute Medical, Inc.


04/07/16
20160096894 
 Antibodies to insulin-like growth factor i receptor patent thumbnailAntibodies to insulin-like growth factor i receptor
The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor i receptor (igf-ir), which is preferably human igf-ir. The invention also relates to human anti-igf-ir antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins.
Amgen Fremont Inc.


04/07/16
20160096839 
 Pyrimidinones as factor xia inhibitors patent thumbnailPyrimidinones as factor xia inhibitors
Or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor xia inhibitors or dual inhibitors of fxia and plasma kallikrein.

04/07/16
20160096823 
 Aminopyridyloxypyrazole compounds patent thumbnailAminopyridyloxypyrazole compounds
The present invention relates to novel aminopyridyloxypyrazole compounds that inhibit the activity of transforming growth factor beta receptor 1 (tgfβr1), pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, preferably colon cancer, melanoma, hepatocellular carcinoma, renal cancer, glioblastoma, pancreatic cancer, myelodysplastic syndrome, lung cancer, and gastric cancer, and/or fibrosis, preferably liver fibrosis and chronic kidney disease.. .
Eli Lilly And Company


04/07/16
20160095958 
 Bone regeneration using stromal vascular fraction, platelet-derived growth factor-rich hydrogel, three-dimensional printed poly-epsilon-caprolactone scaffolds patent thumbnailBone regeneration using stromal vascular fraction, platelet-derived growth factor-rich hydrogel, three-dimensional printed poly-epsilon-caprolactone scaffolds
The presently disclosed subject matter focuses on recapitulating the heterotypic interactions needed to maximize the co-development of vasculature and bone. More particularly, the presently disclosed subject matter explores the potential of cellular aggregation and temporal presentation of factors to induce the cell-cell signaling events required to stimulate ascs to self-organize into vascularized bone.
The Johns Hopkins University


04/07/16
20160095888 
 Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders patent thumbnailMethods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
This invention discloses methods of using krill oil and compositions comprising krill oil to treat risk factors for metabolic, cardiovascular, and inflammatory disorders. The present invention also relates to methods of using compositions comprising krill oil to modulate biological processes selected from the group consisting of glucose metabolism, lipid biosynthesis, fatty acid metabolism, cholesterol biosynthesis, and the mitochondria respiratory chain.
Aker Biomarine Antarctic As


04/07/16
20160095842 
 Combination therapy containing a pi3k-alpha inhibitor and fgfr kinase inhibitor for treating cancer patent thumbnailCombination therapy containing a pi3k-alpha inhibitor and fgfr kinase inhibitor for treating cancer
A pharmaceutical combination comprising an alpha-isoform specific phosphatidylinositol 3-kinase inhibitor compound of formula (i) or a pharmaceutically acceptable salt thereof and a fibroblast growth factor receptor (fgfr) kinase inhibitor, particularly for simultaneous, separate or sequential use for the treatment of a cancer; use of such pharmaceutical combination for the preparation of a medicament for the treatment of a cancer; use of such pharmaceutical combination for the treatment a cancer; a method for treating a cancer comprising administering to a subject having said cancer a jointly therapeutically effective amount of such combination; and related pharmaceutical compositions or kits thereof.. .

04/07/16
20160095544 
 Hand held smell test patent thumbnailHand held smell test
A hand held olfactory tester includes an elongated housing (12) with an opening at its forward end (30) thereof. An odorant chamber (22) located within the housing moveable axially between a forward (fig.
Sensonics, Inc.


03/31/16
20160094990 
 Enhanced two-factor verification for device pairing patent thumbnailEnhanced two-factor verification for device pairing
A novel method for out-of-band key verification that improves on both the usability and the security of the numeric-code method is provided. The method use portions of the generated keys as inputs to perform procedural image generation to produce a visualization at each of the two devices that the user can visually compare and confirm.
Apple Inc.


03/31/16
20160094089 
 Form factor swappable dc battery back-up patent thumbnailForm factor swappable dc battery back-up
In accordance with the present disclosure, a system and method for providing a battery back-up unit (bbu) for a rack-level power infrastructure is described. The system may include a chassis sized to fit within a commodity power supply unit (psu) slot in a power distribution unit (pdu).
Dell Products L.p.


03/31/16
20160090675 

Automatic thread tensioning


A system and method are provided for selectively controlling a thread tension in a quilting machine. The thread tensioner is moveable to a reduced tension configuration in response to an actuator, wherein the actuator is sized to be located within an existing form factor.
Abm International, Inc.


03/31/16
20160090633 

Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor


Disclosed herein are methods of identifying a cancer patient that will be responsive to treatment with a fibroblast growth factor receptor (fgfr) inhibitor and methods of treating cancer patients. The methods involve evaluating a biological sample from the patient for the presence of one or more fgfr mutants from a fgfr mutant gene panel.
Janssen Pharmaceutica Nv


03/31/16
20160090600 

Composition for external application comprising transcription factor decoy as active ingredient


The present invention provides an external preparation composition of transcription factor decoy of good skin permeability, the composition comprising a transcription factor decoy dissolved in a fatty acid-based ionic liquid obtained from a fatty acid having 2 to 20 carbon atoms and an organic amine compound having 4 to 12 carbon atoms.. .
Medrx Co., Ltd.


03/31/16
20160090424 

Stable formulations of immunoglobulin single variable domains and uses thereof


The present invention relates to stable formulations of polypeptides, e.g. Immunoglobulin single variable domains, in particular immunoglobulin single variable domains directed against von willebrand factor (vwf).
Ablynx N.v.


03/31/16
20160090414 

Binding proteins specific for insulin-like growth factors and uses thereof


Binding proteins, such as antibodies directed to igf-ii with cross-reactivity to igf-i and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the igf-ii with cross-reactivity to igf-i are disclosed.
Medimmune Limited


03/31/16
20160089855 

Morphing form factor material


Particular embodiments described herein provide for a morphing material that may include an outer layer, a polymer layer, and an inner core. The polymer layer can be between the inner core and the outer layer.
Intel Corporation


03/31/16
20160089313 

Method for searching for malodor control agent, malodor control agent, and malodor control method


Provided are a method for searching for a malodor inhibitor by using the response of an olfactory receptor as an indicator; a method for inhibiting malodor based on the antagonism of olfactory receptors; and a malodor inhibitor. Disclosed are a method for searching for a malodor inhibitor, the method including: adding a test substance and a malodor-causing substance to any one olfactory receptor selected from the group consisting of or51e1, or2w1, or10a6, or51i2, and or51l1, measuring the response of the olfactory receptor to the malodor-causing substance, identifying the test substance that suppresses the response of the olfactory receptor on the basis of the measured response, and selecting the identified test substance as a malodor inhibitor; an antagonist to any one olfactory receptor selected from the group consisting of or51e1, or2w1, or10a6, or51i2, and or51l1; a method for inhibiting malodor using the antagonist..
Kao Corporation


03/24/16
20160086278 

Risk factor splitting


factor-based performance attribution results are often used to identify portfolio exposures or bets that either perform well or underperform. By identifying particular exposures or bets that appear to be opportune to be increased or reduced, the overall performance of the portfolio can potentially be improved.
Axioma, Inc.


03/24/16
20160086261 

Method and system for providing just in time access to earned but unpaid income and payment services


Methods and systems (including associated devices) are disclosed herein that allow for the providing of one or more financial services, including the facilitating of access to accrued but unpaid earnings, to users such as employees of employers. In at least some embodiments, the extent to which services can be accessed or used is determined at least in part based upon one or more risk determinations.
Payactiv, Inc.


03/24/16
20160085059 

Small form factor telephoto camera


A compact telephoto lens system that may be used in a small form factor cameras. The lens system may include five lens elements with refractive power.
Apple Inc.


03/24/16
20160084978 

Adaptable seismic source for seismic surveys and method


Method, source array and seismic vibro-acoustic source element for seismic data acquisition. The method includes storing in a controller a library of beam form factor sets associated with a source array and corresponding regions to be surveyed; towing the source array along survey lines over the regions to be surveyed; selecting a beam form factor set from the library to be applied to the source array for each region; and actuating the source array based on the selected set of beam form factors and a position of the source array relative to the regions.
Cgg Services Sa


03/24/16
20160083743 

Plants having enhanced yield-related traits and a making the same


The present invention relates generally to the field of molecular biology and concerns a method for enhancing yield-related traits in plants by modulating expression in a plant of a nucleic acid encoding a fsm1-like (fruit sant/myb) polypeptide, or a pif3-like (phytochrome interacting factor) polypeptide, or an uroporphyrinogen iii decarboxylase (urod) polypeptide, or an as-mtt (abiotic stress membrane tethered transcription factor) polypeptide, or an exo-1 polypeptide, or a yiap2 (yield increasing apetala 2) polypeptide. The present invention also concerns plants having modulated expression of a nucleic acid encoding a fsm1-like polypeptide, which plants have enhanced yield-related traits relative to corresponding wild type plants or other control plants.
Basf Plant Science Company Gmbh


03/24/16
20160083739 

Method for modulating expression of specific protein using specific transcription factor, isoprenoid-producing plant having transgene encoding specific transcription factor, and producing polyisoprenoid using isoprenoid-producing plant


The present invention provides methods for enhancing the polyisoprenoid biosynthesis pathway. The present invention further provides isoprenoid-producing plants having an enhanced polyisoprenoid biosynthesis pathway, and methods for producing a polyisoprenoid using such an isoprenoid-producing plant.
Sumitomo Rubber Industries, Ltd.


03/24/16
20160083692 

Electroactive polymeric scaffolds and delivering nerve growth factor to nerve tissue


A polymerizable unit that yields an electrochemically responsive polymer (advantageously pyrrole) is anchored by polymerization within a polycaprolactone matrix to form an electroactive scaffold upon which cells can be cultured and in which the micro- and nano-topological features of the polycaprolactone matrix are preserved. A scaffold manufactured in accordance with the preferred embodiment can support schwann cells, which produce nerve growth factor when electrically stimulated.
University Of Florida Research Foundation, Incorporated


03/24/16
20160083480 

Bispecific her2 and her3 antigen binding constructs


Described herein are isolated bi-specific antigen binding constructs, e.g., antibodies. The bi-specific antigen binding constructs include two antigen binding polypeptide constructs, e.g., a fab and an scfv.
Zymeworks Inc.


03/24/16
20160083464 

Functional monoclonal antibody against heparin-binding epidermal growth factor-like growth factor


Two types of antibodies (35-1 antibody and 292 antibody) capable of binding to phenylalanine at position 115, isoleucine at position 117, glycine at position 140, glutamic acid at position 141, and arginine at position 142 of a human hb-egf protein were successfully obtained. Then, it was also found that these antibodies had an activity of suppressing cleavage of the human hb-egf protein, and an activity of suppressing egfr phosphorylation that would occur when the human hb-egf bound to the egfr.
Medical & Biological Laboratories Co., Ltd.


03/24/16
20160083451 

Methods and systems for zinc delivery using intrinsic factor or haptocorrin


Improved delivery of zinc using haptocorrin or intrinsic factor modified to include a zinc binding sequence that can outcompete dietary zinc inhibitors such as phytin. Known zinc binding sequences can be assayed to determine competitiveness with respect to phytin and, if successful, incorporated into the b12 binding site of haptocorrin or intrinsic factor.
Syracuse University


03/24/16
20160082155 

Bone repair product and methods of use thereof


Provided herein is a bone repair composition that is composed of periosteum containing an angiogenic growth factor(s), cancellous bone chips containing viable osteogenic cells, and, optionally, demineralized bone matrix (dbm) chips. Also provided herein are articles of manufacture and methods of use thereof to treat bone defects..
Osiris Therapeutics, Inc.


03/24/16
20160082154 

Method and system for treatment of damaged biological tissue


Biomaterial compositions and articles comprising mesothelial tissue and a growth factor, for treating damaged biological tissue; particularly, damaged cardiovascular tissue. The biomaterial compositions and articles induce modulated healing, including modulation of inflammation and induced neovascularization, when administered to damaged biological tissue..
Cormatrix Cardiovascular, Inc.


03/24/16
20160082153 

Method and system for treatment of damaged biological tissue


Biomaterial compositions and articles comprising mesothelial tissue and a glycosaminoglycan (gag), for treating damaged biological tissue; particularly, damaged cardiovascular tissue. The biomaterial compositions and articles can also include additional biologically active agents, such as growth factors.
Cormatrix Cardiovascular, Inc.


03/24/16
20160082084 

Heart failure treatment


The present invention relates to treating and/or preventing heart failure or one or more individual heart failure phenotypes in mammals using placental growth factor 2 (plgf-2).. .
Cobiores Nv


03/24/16
20160082083 

Method of inhibiting angiogenesis, tumorigenesis and cathepsin activity


Insulin-like growth factor binding proteins (igfbps) and variants thereof, including igfbp-1, igfbp-2, igfbp-3, igfbp-4, igfbp-5, igfbp-8 and the c-terminal fragments thereof, inhibit angiogenesis, tumorigenesis and cathepsin activity, particularly cathepsin b activity.. .
National Research Council Of Canada


03/24/16
20160082047 

Compositions containing platelet contents


This document provides methods and materials relating to platelet lysates. For example, methods and materials for using platelet lysate compositions to grow adult stem cells, to differentiate adult stem cells, to grow primary cell cultures, to grow tumor stem cells, and to identify effective growth factors are provided..
Mayo Foundation For Medical Education And Research


03/24/16
20160081913 

Composition for stimulating hair growth or preventing hair loss which includes extract neural stem cell and producing same


The present invention relates to a composition for stimulating hair growth or preventing hair loss, which contains a conditioned medium or extract of neural stem cells (nscs) isolated from the ventricular zone of the human brain, and to a preparation method thereof. The conditioned medium or extract of neural stem cells according to the present invention contains various growth factors and cytokines, and thus has an excellent effect on the stimulation of hair growth.
Korea University Research And Business Foundation


03/24/16
20160081658 

Method and system for registering a medical image with a graphical model


An ultrasound imaging system and method includes accessing a graphical model of a representative patient, accessing a medical image of an anatomical structure, and registering the medical image with the graphical model to generate a composite image. The imaging system and method includes displaying the composite image and simultaneously displaying an unregistered medical image of the anatomical structure with the composite image.
General Electric Company


03/17/16
20160078703 

Secure electronic compartment identifier system


A latch, or tag that can be used on luggage, baggage, trunks, rail cars, trailers or any compartment that can be opened and closed that establishes profile data that is associate with the latch or tag and is adapted to store personal data and an identifier in the latch mechanism or on the tag. The profile data can be used to establish a risk factor with the luggage or compartment and/or a person associated with the luggage or compartment..

03/17/16
20160078544 

System for optimizing premium data


According to some embodiments, systems, methods, apparatus, computer program code and means may facilitate calculation of an insurance premium for an insurance product. Insurance risk factor data associated with the insurance product may be received along with insurance loss experience data.
Hartford Fire Insurance Company


03/17/16
20160078309 

Apparatus and methods for identifying and evaluating bright spot indications observed through optical coherence tomography


Exemplary embodiments of the present disclosure include apparatus and methods for identifying bright spot indications observed through optical coherence tomography. The indications can be evaluated, for example, to link risk factors or other conditions to clinically relevant outcomes..
Research Development Foundation


03/17/16
20160077109 

Clinical diagnosis of hepatic fibrosis using a novel panel of human serum protein biomarkers


The inventors have proposed a novel panel of human serum protein biomarkers for diagnosing hepatic fibrosis and cirrhosis. Presently there is no reliable non-invasive way of assessing liver fibrosis.
The Chancellor, Masters And Scholars Of The University Of Oxford


03/17/16
20160076078 

Reagent for measuring total protein s activity


A reagent is used for measuring a total protein s activity in a specimen of a patient to detect protein s abnormality. The reagent includes a first reagent containing at least activated protein c, a first phospholipid, a first surfactant, and calcium ions; a second reagent containing at least activated blood coagulation factor v, the first phospholipid, the first surfactant, and the calcium ions; and a third reagent containing at least activated blood coagulation factor x, prothrombin, a substrate of thrombin, a second phospholipid having a composition different from that of the first phospholipid, and the calcium ions.
School Corporation Kyushu Bunka Gakuen


03/17/16
20160075715 

Substituted tetrahydroisoquinoline compounds as factor xia inhibitors


Or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor xia and/or plasma kallikrein which may be used as medicaments..

03/17/16
20160075492 

Lid for container


A lid for a container is described. The lid has a basin that is designed to enhance the user's olfactory experience when drinking a beverage from the container and lid.
Harl-bella Holdings, Llc


03/17/16
20160075491 

Lid for container


A lid for a container is described. The lid has a basin that is designed to enhance the user's olfactory experience when drinking a beverage from the container and lid.
Harl-bella Holdings, Llc


03/17/16
20160075490 

Lid for container


A lid for a container is described. The lid has a basin that is designed to enhance the user's olfactory experience when drinking a beverage from the container and lid.
Harl-bella Holdings, Llc


03/17/16
20160075489 

Lid for container


A lid for a container is described. The lid has a basin that is designed to enhance the user's olfactory experience when drinking a beverage from the container and lid.
Harl-bella Holdings, Llc


03/17/16
20160075152 

Image recording device having a compact form factor


An image recording device is provided, having a recording unit configured to record an image on a sheet, and a tray disposed below the recording unit. The tray includes a sheet holding surface configured to hold the sheet.
Brother Kogyo Kabushiki Kaisha


03/17/16
20160075151 

Image recording device having a compact form factor


An image recording device is provided, having a recording unit configured to record an image on a sheet, and a tray disposed below the recording unit. The tray includes a sheet holding surface configured to hold the sheet.
Brother Kogyo Kabushiki Kaisha


03/17/16
20160074481 

Clottable concentrate of platelet growth factors and preparation method thereof


The present disclosure relates to a clottable concentrate of platelet growth factors for therapeutic and/or cosmetic use, preferably comprising the growth factors pdgf, tgt-β, igf, egf, ctgf, bfgf and vegf. In a preferred embodiment, the clottable concentrate of platelet growth factors does not induce blood cell-related transfusion reactions.
Zheng Yang Biomedical Technology Co., Ltd.


03/17/16
20160074476 

Modulation of heparin-binding epidermal growth factor activity for tympanic membrane healing


Compositions and methods are provided for the generation or treatment of chronic tympanic membrane perforation by modulation of hb-egf activity.. .
The Board Of Trustees Of The Leland Stanford Juinor University


03/17/16
20160074399 

Salts of an epidermal growth factor receptor kinase inhibitor


The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of egfr kinases and which exhibits desirable characteristics for the same. Examples include hydrobromide and bis-besylate salts of n-(3-(2-(4-(4-acerylpiperazin-1-yl)-2-methoxyphenylamino)-5-(trifluoromethyl)pyrimidin-4-ylamino)phenyl)acrylamide).
Clovis Oncology, Inc.


03/17/16
20160073944 

Olfactory means useful in the diagnosis and treatment of mood depression


A kit of two compositions comprising the same odorants in mixtures of different proportions is used for the measurement of olfactory discrimination capacity in subjects affected by a psychiatric disorder or disease involving mood disturbance, more particularly mood depression.. .
Centre National De La Recherche Scientifique


03/17/16
20160073675 

Nucleic acid sequences encoding transcription factors regulating alkaloid biosynthesis and their use in modifying plant metabolism


Plant metabolism and alkaloid levels can be regulated by transcription factors that regulate the nicotinic alkaloid biosynthetic pathway. In one embodiment, the disclosure provides a transcription factor that negatively regulates alkaloid biosynthesis, such as nicotine biosynthesis..
22nd Century Limited, Llc


03/17/16
20160073622 

Insect control device


A bait station comprising a housing that comprises a flexible portion; a composition contained on or in the housing and comprising at least one sugar and at least one toxin; an insert or attachment coupled to the housing; at least one olfactory attractant contained in the insert or the attachment; and optionally a container holding a liquid or gel or wick system that enhances the performance of the bait station.. .
Ohio State Innovation Foundation


03/10/16
20160072027 

Optical systems fabricated by printing-based assembly


Provided are optical devices and systems fabricated, at least in part, via printing-based assembly and integration of device components. In specific embodiments the present invention provides light emitting systems, light collecting systems, light sensing systems and photovoltaic systems comprising printable semiconductor elements, including large area, high performance macroelectronic devices.
Semprius, Inc.


03/10/16
20160071517 

Evaluating conversation data based on risk factors


This disclosure describes techniques and architectures for evaluating conversations. In some instances, conversations with users, virtual assistants, and others may be analyzed to identify potential risks within a language model that is employed by the virtual assistants and other entities.
Next It Corporation


03/10/16
20160071217 

System for claim load balancing


According to some embodiments, data may be received indicative of a plurality of insurance claims along with an indication of an appropriate claim segment classification for each insurance claim. A first claim handler may then be automatically selected for a first insurance claim based at least in part on: (i) a first segment classification associated with the first insurance claim, (ii) numbers of other insurance claims currently assigned to claim handlers, and (iii) load factors associated with claim handlers.
Hartford Fire Insurance Company


03/10/16
20160071213 

Factor-factor covariance estimates for risk factor groups in factor risk models


Tools for analyzing the risk of a portfolio of financial investments such as equities, bonds, and the like, are addressed. More particularly, computer based systems, processes and software are addressed for calculating factor risk models and for predicting the risk and tracking error of portfolios.
Axioma, Inc.


03/10/16
20160068908 

Homeobox transcription factor ventx regulates differentiation and maturation of human dendritic cells


The invention relates to human homeobox transcription factor ventx and its regulation of differentiation and maturation of human dendritic cells, and related therapeutic and diagnostic compositions and methods of use.. .

03/10/16
20160068830 

Method for the manufacturing of di-chain proteins for use in humans


This invention relates to a novel method for producing di-chain proteins for use in humans from single-chain precursors, including di-chain clostridial neurotoxins. The method comprises the step of expressing a nucleic acid sequence encoding a single-chain precursor comprising a thrombin-cleavage site and the step of cleaving the single-chain precursor with a human factor xa or a human thrombin, particularly a human thrombin drug product authorized for human therapeutic use.
Merz Pharma Gmbh & Co. Kgaa


03/10/16
20160068812 

Method for culturing skeletal muscle for tissue engineering


The invention provides a nutrient medium composition and associated methods for lengthening the useful life of a culture of muscle cells. Disclosed is a method of culturing mammalian muscle cells, including preparing one or more carriers coated with a covalently bonded monolayer of trimethoxy-silylpropyl-diethylenetriamine (deta); verifying deta monolayer formation by one or more associated optical parameters; suspending isolated fetal rat skeletal muscle cells in serum-free medium according to medium composition 1; plating the suspended cells onto the prepared carriers at a predetermined density; leaving the carriers undisturbed for cells to adhere to the deta monolayer; covering the carriers with a mixture of medium 1 and medium 2; and incubating.
University Of Central Florida Research Foundation, Inc.


03/10/16
20160068805 

Method to expand and transduce cultured human small and large intestinal stem cells


A cell culture media composition for support growth of human si stem cells and epithelium without a feeder layer is presented. The media may also include growth factors including enr and y-27632 that support the survival of stem cell spheroid structures.
The United States Government Represented By The Department Of Veterans Affairs


03/10/16
20160068683 

Effect pigments


The present invention relates to effect pigments which are based on flake-form substrates having a circular form factor of 1.2-2 and are coated with at least one high-refractive-index layer, and to the use thereof, inter alia in paints, coatings, printing inks, plastics and in cosmetic formulations.. .
Merck Patent Gmbh


03/10/16
20160068544 

Novel macrocycles as factor xia inhibitors


Or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor xia inhibitors or dual inhibitors of fxia and plasma kallikrein.

03/10/16
20160068511 

Maleate salts of (e)-n--4-(dimethylamino)-2-butenamide and crystalline forms thereof


The present invention relates to maleate salt forms of (e)-n-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, methods of preparing crystalline maleate salt forms, the associated compounds, and pharmaceutical compositions containing the same. The maleate salts are useful in treating cancers, particularly those affected by kinases of the epidermal growth factor receptor family..
Wyeth Llc


03/10/16
20160067674 

Ligands and methods for isolating or removing proteins


The present disclosure relates generally to sorbents for binding proteins from blood plasma comprising a solid carrier material and an oligopeptide immobilized thereon, which selectively binds the protein from the blood plasma, and to a method for separating autologous proteins from blood plasma wherein the blood plasma is brought in contact with a corresponding sorbent, the desired protein is allowed to bind to the sorbent, the sorbent is separated from the plasma and the protein is subsequently separated from the sorbent. Corresponding sorbents and method allows for the selective isolation of specific blood plasma proteins directly from the blood plasma without having to conduct a tedious fractionation.
Previpharma Ag


03/10/16
20160067383 

Agent for regenerating tympanic membrane or external auditory canal


Provided is a tympanic membrane or ear canal regeneration agent comprising a combination of a gelatin sponge that carries basic fibroblast growth factor (bfgf) and a covering material. The covering material is used not only to fix the gelatin sponge to the affected portion, but also for the purpose of preventing drying and infections to provide a culturing environment that is favorable for regenerating tissue isolated from the outside.
Nobelpharma Co., Ltd.


03/10/16
20160067307 

Methods of treating cancer


Methods of treating cancers comprising fgfr1 gene amplification, fgfr1 overexpression, fgfr3 overexpression, fgfr3 amplification, fgf2 overexpression, and/or fgf2 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (fgfr1) extracellular domain (ecd) and/or an fgfr1 ecd fusion molecule.
Glaxosmithkline Intellectual Property (no.2) Limited


03/03/16
20160065608 

Monitoring security risks to enterprise corresponding to access rights and access risk calculation


A system comprising an interface and a memory communicatively coupled to a processor retrieves access information corresponding to an asset. The system stores one or more risk categories and one or more risk factors.
Bank Of America Corporation


03/03/16
20160065357 

Multi-lane n-factorial (n!) and other multi-wire communication systems


System, methods and apparatus are described that facilitate transmission of data over a multi-wire data communications link, particularly between two devices within an electronic apparatus. A clock extracted from a first sequence of symbols transmitted on a first lane of a multi-lane interface is used to receive and decode the first sequence of symbols and to receive and decode data and/or symbols transmitted on a second lane of the multilane interface.
Qualcomm Incorporated


03/03/16
20160064261 

Dispatching method and system


A method of dispatching wafer lots through a plurality of process chambers, wherein the process chambers are disposed in at least one machine. The method includes: receiving wafer lot information and process chamber data, wherein the wafer lot information identifies the wafer lots to be processed at the machine, and the process chamber data includes process information associated with the process chambers; determining a load factor of each process chamber based on the wafer lot information and process chamber data; receiving historical data of run lots previously processed through the process chambers, and determining a processing time of the wafer lots based on the historical data; generating a dispatching criteria for the wafer lots based on the load factors of the process chambers and the determined processing time of the wafer lots; and dispatching the wafer lots through the process chambers based on the dispatching criteria..
Semiconductor Manufacturing International (shanghai) Corporation


03/03/16
20160063631 

System and dynamic risk management


A network interface receives portfolio data related to an investment plan portfolio of a participant. A processor identifies a first plurality of risk factors associated with market conditions, wherein the first plurality of risk factors comprises a future data and risk strength.
Jpmorgan Chase Bank, N.a.


03/03/16
20160063200 

Assessing risks for professionals


Malpractice risk and other risk factors can be associated with online ratings of professionals to assess and categorize malpractice risk and other risk factors for those professionals. Analysis of malpractice risk includes gathering online ratings data for professionals and analyzing the aggregated data in conjunction with malpractice or other risk data and other demographic information of the same or similar professionals to determine statistically significant correlations and algorithms.

03/03/16
20160060648 

Transgenic plants with enhanced agronomic traits


This invention provides transgenic plant cells with recombinant dna for expression of arabidopsis thaliana heat stress transcription factor a-2, which is useful for imparting enhanced agronomic traits) to transgenic crop plants. This invention also provides transgenic plants and progeny seed comprising the transgenic plant cells where the plants are selected for having an enhanced trait selected from the group of traits consisting of enhanced water use efficiency, enhanced cold tolerance, increased yield, enhanced nitrogen use efficiency, enhanced seed protein and enhanced seed oil.
Monsanto Technology Llc


03/03/16
20160060646 

Nucleic acid sequences encoding transcription factors regulating alkaloid biosynthesis and their use in modifying plant metabolism


Plant metabolism and alkaloid levels can be regulated by transcription factors that regulate the nicotinic alkaloid biosynthetic pathway. In one embodiment, the disclosure provides a transcription factor that negatively regulates alkaloid biosynthesis, such as nicotine biosynthesis..
22nd Century Limited, Llc


03/03/16
20160060645 

Nucleic acid sequences encoding transcription factors regulating alkaloid biosynthesis and their use in modifying plant metabolism


Plant metabolism and alkaloid levels can be regulated by transcription factors that regulate the nicotinic alkaloid biosynthetic pathway. In one embodiment, the disclosure provides a transcription factor that negatively regulates alkaloid biosynthesis, such as nicotine biosynthesis..
22nd Century Limited, Llc


03/03/16
20160060612 

Method of isolating and purifying fusion protein comprising factor vii


The present invention provides a method of isolating and purifying a fusion protein comprising factor vii, and more specifically relates to a method of isolating and purifying a fusion protein comprising factor vii and transferrin, to a high degree of purity. Because the present invention provides a method whereby a recombinant fusion protein comprising factor vii can be isolated and purified to a high degree of purity, the invention is useful in producing a pharmaceutical preparation comprising factor vii that can be used in situations in which copious bleeding occurs such as surgery..
Sk Chemicals Co., Ltd.


03/03/16
20160060364 

Low-molecular-weight glycosaminoglycan derivative containing terminal 2, 5-anhydrated talose or derivative thereof


A low-molecular-weight fucosylated glycosaminoglycan (atfg) containing 2,5-anhydrated talose, alditol, glycosylamine or n-substituted glycosylamine monosaccharide composition thereof, preparation method thereof, pharmaceutical compositions containing the atfg, and use thereof for preventing and/or treating thrombotic diseases are provided. The atfg has potent anticoagulant activity targeting at intrinsic coagulation factor xase, and inhibiting thrombogenesis, and therefore can be used as drugs for preventing and/or treating cardiovascular and cerebrovascular diseases..
Kunming Institute Of Botany, Chinese Academy Of Sciences


03/03/16
20160060334 

Fgf modulation of in vivo antibody production and humoral immunity


The invention provides methods for increasing or decreasing antibody production in vivo by inhibiting or promoting the activity of fibroblast growth factor-2 (fgf2) respectively.. .

03/03/16
20160060324 

Methods and compositions for treating bleeding disorders


The present invention provides immune conjugates for inducing antigen specific immune tolerance to coagulation factor viii. The immune conjugates contain a fviii protein or antigenic fragment that is conjugated to a binding moiety for a sialic acid binding ig-like lectin (siglec) expressed on b cells.
The Scripps Research Institute


03/03/16
20160060318 

Means and expression of authentic human epidermal growth factor and/or basic fibrolast growth factor in cytoplasm and/or culture medium of escherichia coli


The present invention relates to an engineered biological system, and in particular an escherichia coli host. The host is incorporated with a dna construct for production of at least a first polypeptide.
Gene-vinate Limited


03/03/16
20160060314 

Development of a protein-based biotherapeutic agent that penetrates cell-membrane and induces anti-tumor effect in solid tumors - improved cell-permeable suppressor of cytokine signaling (icp-socs3) proteins, polynucleotides encoding the same, and anti-tumor compositions comprising the same


In principle, protein-based biotherapeutics offers a way to control biochemical processes in living cells under non-steady state conditions and with fewer off-target effects than conventional small molecule therapeutics. However, systemic protein delivery in vivo has been proven difficult due to poor tissue penetration and rapid clearance.
Cellivery Therapeutics, Inc.


03/03/16
20160060313 

Development of protein-based biotherapeutics that penetrates cell-membrane and induces anti-angiogenic effect - improved cell-permeable suppressor of cytokine signaling (icp-socs3) proteins, polynucleotides encoding the same, and anti-angiogenic compositions comprising the same


In principle, protein-based biotherapeutics offers a way to control biochemical processes in living cells under non-steady state conditions and with fewer off-target effects than conventional small molecule therapeutics. However, systemic protein delivery in vivo has been proven difficult due to poor tissue penetration and rapid clearance.
Cellivery Therapeutics, Inc.


03/03/16
20160060312 

Development of protein-based biotherapeutics that penetrates cell-membrane and induces anti-pancreatic cancer effect - improved cell-permeable suppressor of cytokine signaling (icp-socs3) proteins, polynucleotides encoding the same, and anti-pancreatic cancer compositions comprising the same


In principle, protein-based biotherapeutics offers a way to control biochemical processes in living cells under non-steady state conditions and with fewer off-target effects than conventional small molecule therapeutics. However, systemic protein delivery in vivo has been proven difficult due to poor tissue penetration and rapid clearance.
Cellivery Therapeutics, Inc.


03/03/16
20160060311 

Development of protein-based biotherapeutics that penetrates cell-membrane and induces anti-lung cancer effect - improved cell-permeable suppressor of cytokine signaling (icp-socs3) proteins, polynucleotides encoding the same, and anti-lung cancer compositions comprising the same


In principle, protein-based biotherapeutics offers a way to control biochemical processes in living cells under non-steady state conditions and with fewer off-target effects than conventional small molecule therapeutics. However, systemic protein delivery in vivo has been proven difficult due to poor tissue penetration and rapid clearance.
Cellivery Therapeutics, Inc.


03/03/16
20160060310 

Development of protein-based biotherapeutics that penetrates cell-membrane and induces anti-hepatocellular carcinoma effect - improved cell-permeable suppressor of cytokine signaling (icp-socs3) proteins, polynucleotides encoding the same, and anti-hepatocellular carcinoma compositions comprising the same


Protein transduction exploits the ability of some cell-penetrating peptide (cpp) sequences to enhance the uptake of proteins and other macromolecules by mammalian cells. Previously developed hydrophobic cpps, named membrane translocating sequence (mts), membrane translocating motif (mtm) and macromolecule transduction domain (mtd), are able to deliver biologically active proteins into a variety of cells and tissues.
Cellivery Therapeutics, Inc.


03/03/16
20160060293 

Compositions and treating thrombosis


A peptide, derivative or peptidomimetic the blocks binding of gna12 to αsnap is provided as are methods of using the same to inhibit thrombin-induced von willebrand factor secretion and prevent or treat thrombosis.. .
The Board Of Trustees Of The University Of Illinois


03/03/16
20160060264 

Urea derivatives and uses thereof


The present invention provides novel compounds of any one of formulae (i)-(iii), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of formula (i)-(iii) and pharmaceutical compositions thereof that are mucus penetrating.
Kala Pharmaceuticals, Inc.






Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Factor for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Factor with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.1009

5715

3 - 0 - 115